Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own3.70% Shs Outstand104.59M Perf Week4.95%
Market Cap953.86M Forward P/E- EPS next Y-1.10 Insider Trans20.90% Shs Float91.63M Perf Month24.42%
Income-118.40M PEG- EPS next Q-0.12 Inst Own54.50% Short Float20.62% Perf Quarter59.72%
Sales55.50M P/S17.19 EPS this Y-3.10% Inst Trans0.59% Short Ratio9.65 Perf Half Y104.03%
Book/sh-0.74 P/B- EPS next Y-41.00% ROA-66.60% Target Price14.00 Perf Year170.62%
Cash/sh0.89 P/C10.28 EPS next 5Y5.60% ROE233.40% 52W Range2.05 - 9.26 Perf YTD71.11%
Dividend- P/FCF- EPS past 5Y-20.00% ROI-176.90% 52W High1.30% Beta-
Dividend %- Quick Ratio1.10 Sales past 5Y160.30% Gross Margin- 52W Low357.56% ATR0.56
Employees254 Current Ratio1.10 Sales Q/Q50.30% Oper. Margin- RSI (14)64.67 Volatility5.88% 7.21%
OptionableYes Debt/Eq- EPS Q/Q45.20% Profit Margin- Rel Volume1.49 Prev Close9.12
ShortableYes LT Debt/Eq- EarningsNov 05 BMO Payout- Avg Volume1.96M Price9.38
Recom1.60 SMA2011.69% SMA5023.72% SMA20045.79% Volume1,929,041 Change2.85%
10-Oct-14Resumed Oppenheimer Outperform $9 → $11
08-Jul-14Resumed Brean Capital Buy $16
20-Jun-14Reiterated Oppenheimer Outperform $10 → $8.50
09-Aug-13Reiterated Oppenheimer Outperform $12 → $10
25-Jun-13Initiated Mizuho Buy $12
08-May-12Initiated Oppenheimer Outperform $12
24-Oct-14 06:47AM  Fate Therapeutics (FATE) Crumbles: Stock Tumbles by 10.6% Zacks
06:35AM  Merrimack Pharmaceuticals (MACK) Looks Strong: Stock Up 8.6% Zacks
22-Oct-14 06:43AM  Illumina (ILMN) Looks Strong: Stock Gains 9.2% Zacks
21-Oct-14 02:38AM  Vital Therapies (VTL) in Focus: Stock Adds 7.9% in Session Zacks
02:35AM  NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% Zacks
20-Oct-14 04:24AM  Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% Zacks
17-Oct-14 02:04AM  Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 15.7% Zacks
16-Oct-14 06:23AM  Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% Zacks +6.11%
06:20AM  Synageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% Zacks
15-Oct-14 02:10AM  MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% Zacks
13-Oct-14 06:37AM  Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% Zacks
10-Oct-14 06:47AM  Why Merrimack (MACK) Could Be Positioned for a Surge? Zacks
07-Oct-14 04:01PM  Get Ready To Be Surprised This Earnings Season Zacks -5.19%
06-Oct-14 02:28PM  Top 5 Biotech Stocks Over The Past Year Benzinga
30-Sep-14 08:00AM  Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer GlobeNewswire
29-Sep-14 07:15AM  How Merrimack Pharmaceuticals (MACK) Stock Stands Out in a Strong Industry Zacks
26-Sep-14 09:12AM  3 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
09:10AM  Will Merrimack (MACK) Continue to Surge Higher? Zacks
07:37AM  Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session Zacks
25-Sep-14 04:24PM  Skechers and Apple are big market movers AP +7.37%
12:10PM  Baxter and Merrimack Collaborate on Drug Development Zacks
24-Sep-14 11:42AM  Midday movers: Hasbro, KB Home, Transocean & more at CNBC
10:30AM  Why Merrimack Pharmaceuticals (MACK) Stock Hit a One-Year High Today at TheStreet
10:14AM  Merrimack, Baxter to collaborate on cancer drug AP
09:51AM  US STOCKS-Wall St climbs after three-day slump; housing data on tap Reuters
08:21AM  US STOCKS-Bed, Bath & Beyond, Merrimack Pharma surge in premarket Reuters
08:14AM  Merrimack Does Well to License Marginal Cancer Drug to Baxter at TheStreet
08:08AM  Baxter to market Merrimack's cancer drug outside U.S. Reuters
07:53AM  Merrimack Pharma shares surge on licensing pact with Baxter at MarketWatch
07:43AM  [$$] Baxter, Merrimack to Collaborate on Pancreatic Cancer Drug at The Wall Street Journal
07:15AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materi EDGAR Online
07:00AM  Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 Business Wire
20-Sep-14 09:10AM  10 Stocks Trading Under $10 With Huge Upside Potential at 24/7 Wall St.
19-Sep-14 08:00AM  Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress GlobeNewswire
12-Sep-14 08:59AM  5 Stocks Under $10 Soaring Higher at TheStreet
10-Sep-14 06:41AM  Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? Zacks
09-Sep-14 06:42AM  Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? Zacks
08-Sep-14 02:25PM  3 Cheap Biotech Stocks Analysts Love: Ohr Pharmaceutical Inc, Merrimack & Amicus Benzinga
28-Aug-14 06:58AM  Is Merrimack Pharmaceuticals (MACK) Stock a Solid Choice Right Now? Zacks
19-Aug-14 01:04PM  MERRIMACK PHARMACEUTICALS INC Financials EDGAR Online Financials
11-Aug-14 07:18AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
07:07AM  Q2 2014 Merrimack Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
07:05AM  Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval GlobeNewswire
07:00AM  Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results GlobeNewswire
07-Aug-14 08:20AM  4 Biotech Stocks Where Analysts See 100% Upside, or Even Higher at 24/7 Wall St. +5.03%
04-Aug-14 04:01PM  Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call GlobeNewswire
08-Jul-14 11:17AM  Is Now The Time To Buy Merrimack Pharmaceuticals? at Seeking Alpha
03-Jul-14 10:36AM  4 Biotech Stocks Worth A Look Ahead Of FDA Approvals Benzinga
30-Jun-14 11:37AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an EDGAR Online
28-Jun-14 09:21AM  Key Stocks With Insider Buying This Week at 24/7 Wall St.
25-Jun-14 04:05PM  Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer GlobeNewswire
12:53PM  5 Stocks With Big Insider Buying at TheStreet
24-Jun-14 08:04PM  Why Micron Technology, Qihoo 360, and Merrimack Pharmaceuticals Rose Today at Motley Fool +5.76%
23-Jun-14 03:45PM  Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights Zacks
02:55PM  Nasdaq stocks posting largest percentage decreases
07:45AM  Merrimack Pharmaceuticals (MACK) Crumbles: Stock Tanks by 11.3% Zacks
22-Jun-14 10:17AM  2 Top Catalysts This Week: AstraZeneca and Merrimack at Motley Fool
20-Jun-14 08:34PM  Why Hercules Offshore, Merrimack Pharmaceuticals, and Smith & Wesson Holdings Tumbled Today at Motley Fool -11.28%
11:38AM  Merrimack Pharmaceuticals: The Sleeping Giant Of Cancer Care at Seeking Alpha
11:34AM  Midday movers: Alstom, CarMax, Sprint & More at CNBC
09:08AM  Today's Top Biotech Stocks to Watch: AbbVie, Merrimack Pharmaceuticals, and Shire plc at Motley Fool
19-Jun-14 07:52PM  Why Merrimack Pharmaceuticals Inc. Shares Plunged in After Hours at Motley Fool
04:47PM  Why Merrimack Pharmaceuticals (MACK) Stock is Down in After-Hours Trading Today at TheStreet
04:29PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement EDGAR Online
04:14PM  Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121 GlobeNewswire
17-Jun-14 08:00AM  Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer GlobeNewswire
05-Jun-14 01:44PM  3 Reasons Why Wall Street Hates Merrimack Pharmaceuticals at Motley Fool
02-Jun-14 04:00PM  Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting GlobeNewswire
08:00AM  Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers GlobeNewswire
27-May-14 08:00AM  Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference GlobeNewswire +6.38%
22-May-14 05:23PM  Merrimack Pharmaceuticals to Present Clinical Data Across Oncology Pipeline at ASCO 2014 GlobeNewswire +7.14%
08:40AM  Three Companies That Want to Cure Pancreatic Cancer 24/7 Wall St.
19-May-14 10:06AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to EDGAR Online
16-May-14 12:01PM  Merrimack Pharmaceuticals: Setting The Record Straight On MM 398 at Seeking Alpha
14-May-14 07:00AM  Merrimack Pharma and the Marginal Benefit of Pancreatic Cancer Drug MM-398 at TheStreet
09-May-14 02:41PM  5 Stocks Ready for Breakouts at TheStreet
08-May-14 06:22AM  The Zacks Analyst Blog Highlights: Endocyte, Acorda, Pharmacyclics, OncoGenex and Merrimack Zacks -5.90%
07-May-14 04:01PM  Merrimack Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference GlobeNewswire
06-May-14 04:29PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
10:00AM  The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure at TheStreet
09:29AM  Merrimack Pharmaceuticals: The Long Case at Seeking Alpha
05-May-14 12:20PM  Is Merrimack Pharmaceuticals Worth More Than $700 Million? at Motley Fool +6.84%
02-May-14 06:03PM  Nasdaq stocks posting largest percentage increases AP -8.01%
06:03PM  Most active Nasdaq-traded stocks AP
01:06PM  Today's 3 Biotech Blow-Ups at Motley Fool
08:19AM  Short These Merrimack MM-398 Phase III Data at Seeking Alpha
06:43AM  Merrimack Pharmaceuticals, Inc. (MACK) Appears Robust as Stock Shoots up 59.2% Zacks
01-May-14 06:32PM  Up 50%: Merrimack Pharmaceuticals' Groundbreaking News at Motley Fool +59.23%
06:08PM  Nasdaq stocks posting largest volume increases AP
05:54PM  Merrimack climbs on pancreatic cancer drug study AP
04:52PM  Why Merrimack Pharmaceuticals (MACK) Stock Hit a One-Year High Today (Update) at TheStreet
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for the treatment of various cancers; MM-121, a human monoclonal antibody that targets the ErbB3 cell surface receptor, which is in multiple ongoing Phase I and Phase II clinical trials to inhibit cancer growth directly; and MM-111, a bispecific antibody that is in multiple ongoing Phase I and Phase II clinical trials to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor. The company's product candidates also include MM-302, an antibody drug conjugated liposomal doxorubicin that is in Phase I clinical trials for advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trials for refractory solid tumors; and MM-141, a human tetravalent bispecific antibody that is in Phase I clinical trials to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3. Its therapeutic oncology product candidates are used in the treatment of various cancers, including pancreatic, colorectal, gastric, glioma, ovarian, breast, lung, and other gynecological cancers. The company has collaboration and license agreements with Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, University of California, U.S. Public Health Service, and Selexis SA. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stewart Edward J.SVP & Pres, Healthcare SolOct 15Option Exercise1.714,0006,84025,385Oct 17 04:44 PM
Stewart Edward J.SVP & Pres, Healthcare SolOct 15Sale8.004,00032,00021,385Oct 17 04:44 PM
Sullivan William A.CFO and TreasurerSep 30Option Exercise2.6940,878109,96251,878Oct 01 05:04 PM
Sullivan William A.CFO and TreasurerSep 30Sale8.9440,878365,44911,000Oct 01 05:04 PM
Sullivan William A.CFO and TreasurerSep 29Option Exercise2.1264,404136,53675,404Oct 01 05:04 PM
Sullivan William A.CFO and TreasurerSep 29Sale8.4064,404540,99411,000Oct 01 05:04 PM
Stewart Edward J.SVP & Pres, Healthcare SolSep 24Option Exercise1.7112,00020,52033,385Sep 26 04:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolSep 24Sale8.2212,00098,64021,385Sep 26 04:14 PM
Mulroy Robert J.President and CEOAug 29Option Exercise1.2519,83224,7901,246,069Sep 02 10:45 AM
Nielsen Ulrik B.SVP and CSOAug 26Option Exercise1.2550,00062,500226,811Aug 28 04:25 PM
Stewart Edward J.SVP & Pres, Healthcare SolAug 26Option Exercise1.2524,00030,00045,385Aug 28 04:23 PM
Stewart Edward J.SVP & Pres, Healthcare SolAug 26Sale6.8724,000164,88021,385Aug 28 04:23 PM
Sinskey Anthony JDirectorAug 25Option Exercise1.2525,00031,250422,543Aug 27 08:22 AM
Mulroy Robert J.President and CEOAug 21Option Exercise1.25280,168350,2101,226,237Aug 25 10:04 AM
PORTER MICHAEL EDirectorJun 23Buy6.8432,390221,548568,255Jun 24 09:16 AM
CROCKER GARY LDirectorJun 23Buy6.8436,000246,2402,844,571Jun 24 09:15 AM
Dresser James van B.DirectorJun 02Option Exercise1.2525,00031,250168,974Jun 03 01:26 PM
Stewart Edward J.SVP & Pres, Healthcare SolMay 27Option Exercise1.2516,00020,00037,385May 29 07:17 PM
Nielsen Ulrik B.SVP and CSOMay 27Option Exercise1.27105,000133,550281,811May 29 07:18 PM
Stewart Edward J.SVP & Pres, Healthcare SolMay 27Sale8.0016,000128,00021,385May 29 07:17 PM
Nielsen Ulrik B.SVP and CSOMay 27Sale8.01105,000841,050176,811May 29 07:18 PM
CROCKER GARY LDirectorMay 20Buy6.694,00026,7602,808,571May 22 11:43 AM
Quigley James H.DirectorMay 19Buy6.585,00032,90056,500May 21 07:57 AM
CROCKER GARY LDirectorMay 19Buy6.716,00040,2602,804,571May 20 09:53 AM
CROCKER GARY LDirectorMay 16Buy6.633,40022,5422,798,571May 20 09:53 AM
PORTER MICHAEL EDirectorMay 16Buy6.505,00032,500535,865May 16 02:26 PM
PORTER MICHAEL EDirectorMay 14Buy6.4910,00064,900530,865May 16 02:26 PM
Sinskey Anthony JDirectorMay 13Buy6.745,00033,700397,543May 15 08:18 AM
Fehr Gordon J.DirectorMay 12Option Exercise1.2525,00031,250215,143May 14 02:28 PM
PORTER MICHAEL EDirectorMay 08Option Exercise1.9420,00038,700515,865May 09 01:15 PM
PORTER MICHAEL EDirectorMay 08Buy6.485,00032,400520,865May 09 01:15 PM
PORTER MICHAEL EDirectorMay 07Buy6.705,00033,500495,865May 09 01:15 PM
Nash Sarah EDirectorMay 07Buy6.7915,000101,850955,296May 09 10:57 AM
CROCKER GARY LDirectorMay 07Buy6.774,40029,7882,795,171May 08 10:44 AM
CROCKER GARY LDirectorMay 06Buy6.857,50051,3752,790,771May 07 01:19 PM
CROCKER GARY LDirectorMay 05Option Exercise1.2535,00043,7502,773,271May 06 10:08 AM
CROCKER GARY LDirectorMay 05Buy6.6910,00066,9002,738,271May 06 10:08 AM
PORTER MICHAEL EDirectorMay 05Buy6.4115,00096,150485,865May 05 01:21 PM
PORTER MICHAEL EDirectorMay 05Buy6.125,00030,600490,865May 07 03:02 PM
CROCKER GARY LDirectorMay 05Buy6.9210,00069,2002,783,271May 07 01:19 PM
CROCKER GARY LDirectorMar 12Option Exercise1.2550,00062,5002,728,271Mar 14 08:56 AM